These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32172803)

  • 1. Radium-223 as an Approved Modality for Treatment of Bone Metastases.
    Brito AE; Etchebehere E
    Semin Nucl Med; 2020 Mar; 50(2):177-192. PubMed ID: 32172803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.
    Den RB; George D; Pieczonka C; McNamara M
    Am J Clin Oncol; 2019 Apr; 42(4):399-406. PubMed ID: 30844849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
    Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
    Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
    McGann S; Horton ER
    Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bone and calcium metabolism associated with malignancy. Treatment of radium-223 dichloride for bone metastasis in castration resistant prostate cancer patients.].
    Uemura H
    Clin Calcium; 2018; 28(11):1485-1493. PubMed ID: 30374005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.
    Kluetz PG; Pierce W; Maher VE; Zhang H; Tang S; Song P; Liu Q; Haber MT; Leutzinger EE; Al-Hakim A; Chen W; Palmby T; Alebachew E; Sridhara R; Ibrahim A; Justice R; Pazdur R
    Clin Cancer Res; 2014 Jan; 20(1):9-14. PubMed ID: 24190979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radium 223 for the treatment of metastatic castration-resistant prostate cancer.
    Miranda J; Viñal D; Pinto Á
    Arch Esp Urol; 2019 Jun; 72(5):500-507. PubMed ID: 31223127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of pre-treatment variables on the completion of
    Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
    Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
    Poeppel TD; Handkiewicz-Junak D; Andreeff M; Becherer A; Bockisch A; Fricke E; Geworski L; Heinzel A; Krause BJ; Krause T; Mitterhauser M; Sonnenschein W; Bodei L; Delgado-Bolton RC; Gabriel M
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):824-845. PubMed ID: 29234845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radium-223 in the treatment of bone metastasis in patients with castration-resistant prostate cancer. Review and procedure.
    Orcajo-Rincon J; Caresia-Aróztegui AP; Del Puig Cózar-Santiago M; García-Garzón JR; de Arcocha-Torres M; Delgado-Bolton RC; García-Velloso MJ; Alvarez-Ruiz S; García-Vicente AM
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(5):330-337. PubMed ID: 29661653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
    Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
    J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
    Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
    Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.
    Pacilio M; Ventroni G; De Vincentis G; Cassano B; Pellegrini R; Di Castro E; Frantellizzi V; Follacchio GA; Garkavaya T; Lorenzon L; Ialongo P; Pani R; Mango L
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):21-33. PubMed ID: 26266887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radium-223 in the treatment of osteoblastic metastases: a critical clinical review.
    Humm JL; Sartor O; Parker C; Bruland OS; Macklis R
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):898-906. PubMed ID: 25832684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.
    Rodriguez-Vida A; Torregrosa MD; Pinto Á; Climent MÁ; Olmos D; Carles J
    Clin Transl Oncol; 2018 Jun; 20(6):679-686. PubMed ID: 29098556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer.
    Pratt BE; Hindorf C; Chittenden SJ; Parker CC; Flux GD
    Nucl Med Commun; 2018 Feb; 39(2):125-130. PubMed ID: 29189490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer.
    Buroni FE; Persico MG; Pasi F; Lodola L; Nano R; Aprile C
    Anticancer Res; 2016 Nov; 36(11):5719-5730. PubMed ID: 27793893
    [No Abstract]   [Full Text] [Related]  

  • 18. [Radium-223 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) : The androgen receptor-independent active agent in the therapeutic sequence].
    König F; Strauß A; Johannsen M; Mommsen C; Fricke E; Klier J; Mehl S; Pfister D; Sahlmann CO; Werner A; Goebell PJ
    Urologe A; 2020 Jan; 59(1):53-64. PubMed ID: 31598745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
    Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
    Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radium-223 for the treatment of metastatic castration-resistant prostate cancer: A window of opportunity.
    Gómez-Veiga F; Álvarez-Ossorio JL; Carballido-Rodríguez J; Juárez-Soto A; Rodríguez-Antolín A; Cozar-Olmo JM
    Actas Urol Esp (Engl Ed); 2018 Dec; 42(10):616-624. PubMed ID: 30041891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.